Novel mutations associated with carnitine palmitoyltransferase II deficiency

Area of Science:

• Biochemistry
• Genetics
• Molecular Biology

Background:

• Carnitine palmitoyltransferase II (CPT II) deficiency is a common adult-onset metabolic disorder.
• Symptoms include muscle pain, stiffness, and myoglobinuria, often triggered by metabolic stress.
• Understanding the molecular basis of CPT II deficiency is crucial for diagnosis and management.

Purpose of the Study:

• To investigate the molecular heterogeneity of CPT2 mutations and their biochemical consequences.
• To identify novel mutations and characterize their prevalence in individuals suspected of CPT II deficiency.
• To explore the potential clinical implications of heterozygosity for CPT2 mutations.

Main Methods:

• Screening of 59 individuals with suspected CPT II deficiency.
• Initial screening for 11 known mutations using allele-specific oligonucleotides (ASO).
• Extensive sequence analysis of CPT2 gene for mutation identification.

Main Results:

• Identified three known (P50H, S113L, F448L) and three novel mutations in 13 individuals.
• Discovered a frameshift mutation (413 delAG) in individuals of Ashkenazi Jewish ancestry, suggesting ethnic origin.
• Found that heterozygosity for certain mutations (S113L, R503C) may predispose individuals to clinical symptoms.

Conclusions:

• Molecular analysis revealed significant heterogeneity in CPT2 mutations.
• Novel mutations R503C, G549D, and 413 delAG were identified, with 413 delAG being prevalent in Ashkenazi Jewish individuals.
• Heterozygosity for specific CPT2 mutations can be associated with clinical risk, warranting further investigation.